和黄医药任命胡朝红为独立非执行董事
财中社11月20日电和黄医药（00013/HCM）发布公告，宣布胡朝红博士自2024年11月21日起被委任为公司独立非执行董事及技术委员会成员。胡博士在治疗性抗体、抗体偶联药物及疫苗开发方面拥有超过20年的经验，曾领导多项研发计划，并在生物医药领域展现出强大的领导和创新能力。
胡博士目前是D Biotherapeutics, LLC的首席运营官，并曾在乐普生物科技股份有限公司担任执行董事兼联席总经理。她还曾创办上海美雅珂生物技术有限责任公司，专注于癌症靶向治疗新药的研发。根据公告，她作为独立非执行董事的年薪为7.6万美元，技术委员会成员的年薪为8000美元，薪酬将根据董事职务与责任及市场情况进行调整。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10